About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

[National Medical Products Administration Approves Peleganam Spray for Marketing] On June 22, according to the National Medical Products Administration (NMPA), the NMPA recently approved the marketing of Peleganam Spray (trade name: Puyike), a Class

2026-06-22

[National Medical Products Administration Approves Peleganam Spray for Marketing] On June 22, according to the National Medical Products Administration (NMPA), the NMPA recently approved the marketing of Peleganam Spray (trade name: Puyike), a Class 1 innovative drug submitted by Pulai Pharmaceutical (Jiangsu) Co., Ltd. This product is a topical antibacterial drug indicated for the treatment of wound infections secondary to first-degree or superficial second-degree burns caused by Staphylococcus epidermidis, Staphylococcus hemolyticus, and Acinetobacter baumannii. The approval of this drug provides patients with a new treatment option.

Other News
2026-06-22

U.S. Vice President Vance said he hopes Lebanon's sovereignty will be respected.

U.S. Vice President Vance said he hopes Lebanon's sovereignty will be respected.
2026-06-22

The National Medical Products Administration (NMPA) today released its 2025 Annual Report on New Drug Registration Clinical Trial Progress, showing China’s The total number of drug clinical trials surpassed 5,000 for the first time. The report says 2

The National Medical Products Administration (NMPA) today released its 2025 Annual Report on New Drug Registration Clinical Trial Progress, showing China’s The total number of drug clinical trials surpassed 5,000 for the first time. The report says 248 new drugs received regulatory approval following clinical trials in 2025, covering 18 indication areas including oncology, endocrine and psychiatric disorders.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.